|
|
Vaccine Detail
|
autologous dendritic cells (DCs) |
| Vaccine Information |
- Vaccine Name: autologous dendritic cells (DCs)
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007578
- Type: Dendritic cell vaccine
- Status: Clinical trial
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: increased proportion of Th3 (CD4(+) TGF-β(+)) regulatory T lymphocytes, DTH(+) patients showed a threefold reduction of Th3 cells compared with DTH(-) patients after DCs vaccine treatment, DCs vaccination resulted in a threefold augment of the proportion of IFN-γ releasing Th1 cells and in a twofold increase of the IL-17-producing Th17 population in DTH(+) with respect to DTH(-) patients, Increased Th1 and Th17 cell populations in both blood and DTH-derived tissues(Durán-Aniotz et al., 2013)
|
| References |
Durán-Aniotz et al., 2013: Durán-Aniotz C, Segal G, Salazar L, Pereda C, Falcón C, Tempio F, Aguilera R, González R, Pérez C, Tittarelli A, Catalán D, Nervi B, Larrondo M, Salazar-Onfray F, López MN. The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. Cancer immunology, immunotherapy : CII. 2013; 62(4); 761-772. [PubMed: 23242374].
|
|
